Myriad Genetics Files 8-K on Operations and Financials

TL;DR

MYGN filed an 8-K, expect financial updates soon.

AI Summary

Myriad Genetics, Inc. filed an 8-K on May 7, 2024, reporting on its results of operations and financial condition, as well as filing financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.

Why It Matters

This filing serves as a formal update to investors and the public regarding the company's financial health and operational performance, which can influence investment decisions.

Risk Assessment

Risk Level: low — The filing is a standard corporate disclosure and does not inherently present new risks.

Key Players & Entities

• MYRIAD GENETICS INC (company) — Registrant
• 0000899923-24-000025 (filing_id) — Accession Number
• May 7, 2024 (date) — Date of Report
• Salt Lake City, Utah (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Mar

Filing Documents

• mygn-20240507.htm (8-K) — 36KB
• mygn-xq124earningsreleasex.htm (EX-99.1) — 301KB
• 0000899923-24-000025.txt ( ) — 512KB
• mygn-20240507.xsd (EX-101.SCH) — 2KB
• mygn-20240507_def.xml (EX-101.DEF) — 14KB
• mygn-20240507_lab.xml (EX-101.LAB) — 25KB
• mygn-20240507_pre.xml (EX-101.PRE) — 15KB
• mygn-20240507_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

ITEM 2.02 Results of Operations and Financial Condition. On May 7, 2024, Myriad Genetics, Inc. ("Myriad" or the "Company") announced its financial results for the three months ended March 31, 2024. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Current Report on Form 8-K and Exhibit 99.1 contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the Company's fiscal year 2024 financial guidance, the Company's plans to continue to produce additional clinical validation studies and move closer to the launch of new products, statements relating to the Company's advancement of a number of enhancements to improve access and ease of use for customers, including EMR integrations, and that the Company is growing, delivering improved financial results and is continuing to invest in the innovation required to achieve its Mission and Vision to reach more patients with life-saving precision medicine. These "forward-looking statements" are management's present expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. These risks include, but are not limited to: the risk that sales and profit margins of the Company's existing tests may decline; the risk that the Company may not be able to operate its business on a profitable basis; risks related to the Company's ability to achieve certain revenue growth targets and generate sufficient revenue from its existing product portfolio or in launching and commercializing new tests to be profitable; risks related to changes in governmental or private insurers' coverage and reimbursement levels for the Company's tests or the Company's ability to obtain reimbursement for its new tests at comparable levels to its existing tests; risks related to increased competition and the development of new competing tests; the risk that the Company may be unable to develop or achieve commercial success for additional tests in a timely manner, or at all; the risk that the Company may not successfully develop new markets

01 Financial Statements and Exhibits

ITEM 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Earnings release dated May 7, 2024 for the three months ended March 31, 2024 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). The exhibit(s) may contain hypertext links to information on our website or other parties' websites. The information on our website and other parties' websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K. In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 2.02 and in Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYRIAD GENETICS, INC. Date: May 7, 2024 By: /s/ Scott J. Leffler Scott J. Leffler Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR